Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Short Interest Up 61.8% in April

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) saw a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 174,300 shares, an increase of 61.8% from the March 31st total of 107,700 shares. Currently, 0.7% of the shares of the company are sold short. Based on an average trading volume of 257,400 shares, the days-to-cover ratio is presently 0.7 days.

Institutional Trading of Coeptis Therapeutics

A hedge fund recently raised its stake in Coeptis Therapeutics stock. Armistice Capital LLC lifted its stake in shares of Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) by 59.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,520,000 shares of the company’s stock after purchasing an additional 1,308,000 shares during the quarter. Armistice Capital LLC owned about 10.32% of Coeptis Therapeutics worth $2,759,000 at the end of the most recent reporting period. Institutional investors own 13.88% of the company’s stock.

Coeptis Therapeutics Trading Up 4.0 %

COEP stock opened at $0.33 on Monday. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.03. The firm’s 50-day simple moving average is $0.40 and its 200 day simple moving average is $0.72. Coeptis Therapeutics has a fifty-two week low of $0.29 and a fifty-two week high of $2.19.

Coeptis Therapeutics (NASDAQ:COEP) last announced its quarterly earnings results on Monday, March 25th. The company reported ($0.08) EPS for the quarter. Analysts predict that Coeptis Therapeutics will post -0.77 EPS for the current year.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.